Enanta Pharmaceuticals In... (ENTA)
4.86
-0.17 (-3.38%)
At close: Jan 14, 2025, 3:59 PM
4.95
1.87%
After-hours Jan 14, 2025, 07:36 PM EST
undefined% (undefined)
| Bid | 4.5 |
| Market Cap | 102.98M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.48 |
| PE Ratio (ttm) | -0.89 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.31 |
| Volume | 544,846 |
| Avg. Volume (20D) | 408,683 |
| Open | 5.05 |
| Previous Close | 5.03 |
| Day's Range | 4.84 - 5.08 |
| 52-Week Range | 4.84 - 17.80 |
| Beta | undefined |
About ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A pro...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 2013
Employees 145
Stock Exchange NASDAQ
Ticker Symbol ENTA
Website https://www.enanta.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 291.03% from the latest price.
Buy 75.00%
Hold 0.00%
Sell 25.00%
Next Earnings Release
Enanta Pharmaceuticals Inc. is scheduled to release its earnings on Feb 5, 2025,
during market hours.
Analysts project revenue of $17.25M, reflecting a -4.18% YoY shrinking and earnings per share of -1.35, making a -14.56% decrease YoY.
Analysts project revenue of $17.25M, reflecting a -4.18% YoY shrinking and earnings per share of -1.35, making a -14.56% decrease YoY.
1 month ago ·
Source
+11.75%
Enanta Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
